These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9061296)

  • 21. Genomic alterations in malignant transformation of Barrett's esophagus.
    Riegman PH; Vissers KJ; Alers JC; Geelen E; Hop WC; Tilanus HW; van Dekken H
    Cancer Res; 2001 Apr; 61(7):3164-70. PubMed ID: 11306503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
    Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
    Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barrett's esophagus. The significance of p53 in clinical practice.
    Ireland AP; Clark GW; DeMeester TR
    Ann Surg; 1997 Jan; 225(1):17-30. PubMed ID: 8998117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.
    Doak SH; Jenkins GJ; Parry EM; D'Souza FR; Griffiths AP; Toffazal N; Shah V; Baxter JN; Parry JM
    Gut; 2003 May; 52(5):623-8. PubMed ID: 12692043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
    Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
    Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.
    Galipeau PC; Cowan DS; Sanchez CA; Barrett MT; Emond MJ; Levine DS; Rabinovitch PS; Reid BJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7081-4. PubMed ID: 8692948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
    Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
    J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barrett's oesophagus--a pathologist's view.
    Fléjou JF; Svrcek M
    Histopathology; 2007 Jan; 50(1):3-14. PubMed ID: 17204017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial Barrett's adenocarcinoma.
    Melzer E; Shtoyerman R; Appelman Z; Kashtan H
    Am J Gastroenterol; 2006 Mar; 101(3):677. PubMed ID: 16542304
    [No Abstract]   [Full Text] [Related]  

  • 32. Loss of heterozygosities in Barrett esophagus, dysplasia, and adenocarcinoma detected by esophageal brushing cytology and gastroesophageal biopsy.
    Lin X; Finkelstein SD; Zhu B; Ujevich BJ; Silverman JF
    Cancer; 2009 Feb; 117(1):57-66. PubMed ID: 19347831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barrett's oesophagus and p53.
    Levine DS
    Lancet; 1994 Jul; 344(8917):212-3. PubMed ID: 7913153
    [No Abstract]   [Full Text] [Related]  

  • 34. Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.
    Abraham JM; Meltzer SJ
    Gastroenterology; 2017 Jul; 153(1):27-34. PubMed ID: 28528706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying big GWAS data to clarify the role of obesity in Barrett's esophagus and esophageal adenocarcinoma.
    Abrams JA; Chak A
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25269700
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-1 RN polymorphism is not associated with Barrett's esophagus and esophageal adenocarcinoma.
    Moons LM; Siersema PD; Kuipers EJ; van Vliet AH; Kusters JG
    Am J Gastroenterol; 2005 Dec; 100(12):2818. PubMed ID: 16393246
    [No Abstract]   [Full Text] [Related]  

  • 40. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.